Exec-Edge – Page 18 – ExecEdge

Grove Delivers Positive Cash Flow; Acquires 8Greens, Grab Green

Grove Delivers Positive Cash Flow; Acquires 8Greens, Grab Green

By Karen Roman Grove Collaborative Holdings, Inc. (NYSE: GROV) said annual adjusted EBITDA was $1.3 million, increasing $10.5 million year-over-year. Operating cash flow for Q4 was $0.3 million, making it the third consecutive quarter with positive results, it said. Grove...

Medera Completes Patient Dosing for Heart Failure Treatment

Medera Completes Patient Dosing for Heart Failure Treatment

By Karen Roman Biopharmaceutical company Medera Inc. said it finished patient dosing in the trial of SRD-001, its gene therapy candidate for heart failure with reduced ejection fraction. Additionally, Medera and Keen Vision Acquisition Corporation (Nasdaq: KVAC) announced they had...

Kohl’s 2024 Net Sales Drop as Company Positions for Growth

Kohl’s 2024 Net Sales Drop as Company Positions for Growth

By Daniella Parra Kohl’s Corporation (NYSE: KSS) said net sales fell 9.4% and 7.2% for both fourth-quarter and fiscal year 2024. The company’s diluted EPS for the fourth quarter was $0.43 ($0.95 adjusted), while full-year diluted EPS was $0.98 ($1.50...

The ONE Group Revenue Increased 146.7% in Q4 2024

The ONE Group Revenue Increased 146.7% in Q4 2024

By Karen Roman The ONE Group Hospitality, Inc. (Nasdaq: STKS) said fourth quarter revenue increased 146.7% to $221.9 million from $89.9 million and operating income rose 158.9% to $12.8 million from $4.9 million. The company opened six new restaurants in...

Potbelly Same-Store Sales Increase in Q4 Amid Expansion

Potbelly Same-Store Sales Increase in Q4 Amid Expansion

By Daniella Parra Potbelly Corp. (Nasdaq: PBPB) said its average weekly sales increased 1.1% to $25,230 and company-operated same-store sales in the fourth quarter increased 0.3%. Total revenues decreased 7.3% while adjusted EBITDA increased 30.0% to $9.7 million, they said....

Ascentage Secures Third Breakthrough Therapy for Ph+ ALL Treatment

Ascentage Secures Third Breakthrough Therapy for Ph+ ALL Treatment

By Daniella Parra Ascentage Pharma (NASDAQ: AAPG; HKEX) said that its drug Olverembatinib is the first China-approved third-generation BCR-ABL inhibitor, and has been approved for certain chronic myeloid leukemia (CML) indications and included in China’s National Reimbursement Drug List. Olverembatinib,...

Nanox.ARC Imaging System Granted Certification in EU

Nanox.ARC Imaging System Granted Certification in EU

By Karen Roman Medical tech company Nano-X Imaging Ltd. (Nasdaq: NNOX) said Nanox.ARC, its digital multi-source 3D tomosynthesis imaging system, received CE mark certification in the European market. Nanox.ARC also has FDA clearance for general use in the U.S. and...

Input your search keywords and press Enter.